Company intelligence / Profile preview
Bisirna Therapeutics
Suzhou, Jiangsu, Chinabisirna.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BiSiRNA Therapeutics is a biotechnology company focused on developing next-generation RNA interference (RNAi) therapies to treat cancer. The company's core technology is a proprietary bi-functional siRNA (bi-siRNA) platform that combines both cleavage-dependent and cleavage-independent pathways to achieve more potent and long-lasting gene silencing. Its lead candidate, BSR-01, is a potent siRNA targeting the KRAS G12D mutation, which is a major driver in pancreatic and colorectal cancers. BiSiRNA Therapeutics maintains operations in both Suzhou, China, and the United States, positioning itself to address high-unmet-need oncological indications globally.
- Therapeutic areas
- Oncology
- Modalities
- Small interfering RNARNA therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Bisirna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bisirna Therapeutics.